News tagged with carboplatin
Paragazole excels in preclinical models of triple-negative breast cancer
Breast cancers that lack estrogen receptors are more difficult to treat than ER+ cancers. Research presented at the AACR Annual Meeting 2013 demonstrates an investigational drug, Paragazole, that makes triple-negative ...
Cancer
Apr 08, 2013 |
5 / 5 (2) |
0
Harmless human virus may be able to boost the effects of chemotherapy
A naturally-occurring harmless human virus may be able to boost the effects of two standard chemotherapy drugs in some cancer patients, according to early stage trial data published in Clinical Cancer Research.
Cancer
Apr 03, 2012 |
5 / 5 (1) |
0
Optimal dose suggested for dasatinib in ovarian cancer
(HealthDay)—A phase I trial of dasatinib combined with paclitaxel and carboplatin has determined the optimal dose of dasatinib and suggested some efficacy in women with advanced or recurrent ovarian cancer, ...
Cancer
Nov 19, 2012 |
5 / 5 (1) |
0
Carboplatin
Carboplatin, or cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II) (trade names Paraplatin and Paraplatin-AQ) is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers). It was introduced in the late 1980s and has since gained popularity in clinical treatment due to its vastly reduced side-effects compared to its parent compound cisplatin. Cisplatin and carboplatin, as well as oxaliplatin, interact with DNA, akin to the mechanism of alkylating agents.
For more information about Carboplatin, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
